Overview

Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

The Company has an advanced pipeline of proprietary drug candidates in Phase II and Phase III clinical development which address inflammatory, liver and metabolic diseases.

Can-Fite's platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. The latter is highly expressed in inflammatory, cancer and other pathological body cells,  whereas low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention.

The pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3AR  with nM affinity and induce deregulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects. All drugs are orally bioavailable with an excellent safety profile.

Piclidenoson (CF101), Can-Fite's lead drug candidate, is an oral drug currently in a Phase III clinical study for the treatment of psoriasis and a Phase II study for the treatment of COVID-19. The psoriasis Phase II, Phase II/III and the Phase III interim analysis showed very good clinical activity and safety of the drug. 

Namodenoson (CF102), Can-Fite's second drug candidate, is an oral drug currently being developed for the treatment of liver diseases including hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH).

CF602, an allosteric modulator at the A3AR, is earmarked for the treatment of sexual dysfunction and showed efficacy in preclinical pharmacology studies demonstrating that topical and oral treatment significantly improved erectile function via an increase in smooth muscle/collagen ratio, VEGF and eNOS.

Cannabinoids induce their therapeutic effects via binding to Can-Fite's drug target, the A3AR. Based on this characteristic,  Can-Fite can predict whether a given cannabinoid will be clinically efficacious. This know-how is patent pending. 

Out-Licensing Deals: Piclidenoson for the treatment of psoriasis has been out-licensed to Cipher Pharmaceuticals in Canada; Gebro Pharma GmbH in Spain, Switzerland & Austria; Kyongbo Pharm in Korea; and CMS in China, Taiwan, Hong Kong and Macao. Namodenoson for the treatment of liver cancer and NASH has been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and CMS in China.



An advanced clinical stage
drug development company